Lazard Asset Management
STRO icon

Lazard Asset Management’s Sutro Biopharma STRO Stock Holding History

Lazard Asset Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,095
Closed -$7K – 2287
2025
Q2 		$7K Buy
+1,095
New +$8.95K ﹤0.01% 2187
2024
Q4 		– Sell
-963
Closed -$33K – 2528
2024
Q3 		$33K Buy
+963
New +$37.7K ﹤0.01% 1970
2024
Q2 		– Sell
-1,639
Closed -$92K – 2422
2024
Q1 		$92K Buy
+1,639
New +$72.4K ﹤0.01% 1564
2023
Q1 		– Sell
-1,587
Closed -$128K – 2538
2022
Q4 		$128K Hold
1,587
– – ﹤0.01% 1438
2022
Q3 		$88K Buy
1,587
+902
+132% +$53.4K ﹤0.01% 1520
2022
Q2 		$35K Hold
685
– – ﹤0.01% 1961
2022
Q1 		$56K Buy
+685
New +$65.2K ﹤0.01% 1689
2021
Q4 		– Sell
-280
Closed -$52K – 2451
2021
Q3 		$52K Buy
+280
New +$53.2K ﹤0.01% 1670

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Lazard Asset Management's STRO Position: Q3 2025 in Review

Lazard Asset Management sold out of Sutro Biopharma (STRO) in Q3 2025, closing a stake of 1,095 shares — an estimated $7K sold.

Lazard Asset Management first reported a position in STRO in Q3 2021 and held it in 8 quarters. The position peaked at $128K in Q4 2022. 87 funds tracked by Wall St. Rank hold STRO as of Q3 2025.

  • Lazard Asset Management reported no remaining Sutro Biopharma position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 1,095 Sutro Biopharma shares in Q3 2025, an estimated $7K.
  • Lazard Asset Management first reported a position in Sutro Biopharma in Q3 2021 and held it in 8 quarters.
  • Lazard Asset Management's Sutro Biopharma position peaked at $128K in Q4 2022.
  • 87 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.